Dynavax Technologies | Lånekapital



Loan Capital Endring Dato
AbbVie USD 60.34B 1.83B 2024-12
Adma Biologics USD 72.34M 28.99M 2024-12
Amgen USD 56.55B 305M 2024-12
AstraZeneca USD 27.73B 2.29B 2024-12
Biogen USD 4.55B 1.4M 2024-12
BioMarin Pharmaceutical USD 595.89M 1.27M 2024-12
Bristol-Myers Squibb USD 47.6B 1.07B 2024-12
Dynavax Technologies USD 223.85M 293K 2024-12
Gilead Sciences USD 24.9B 3.46B 2024-12
Glaxosmithkline GBP 14.64B 1.39B 2024-12
Merck USD 34.46B 520M 2024-12
Neurocrine Biosciences USD 0 0 2024-12
Novartis USD 22.93B 2.41B 2024-12
Pfizer USD 57.4B 597M 2024-12
Regeneron Pharmaceuticals USD 2.7B 720.4M 2024-12
Roche Holding CHF 32.1B 1.94B 2024-12
Sarepta Therapeutics USD 1.14B 1.16M 2024-12
TG Therapeutics USD 244.43M 271K 2024-12
Vertex Pharmaceuticals USD 112.8M 1.2M 2024-12



Dynavax Technologies Lånekapital - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Apr 2025.